Marketing Authorizations, Financial Results, Public Offering and Leadership Transitions - Research Report on Regeneron,

 Marketing Authorizations, Financial Results, Public Offering and Leadership
 Transitions - Research Report on Regeneron, Dendreon, Dyax, Techne, and ICU
                                   Medical

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 15, 2013

NEW YORK, November 15, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN), Dendreon Corp. (NASDAQ: DNDN), Dyax
Corp. (NASDAQ: DYAX), Techne Corp. (NASDAQ: TECH), and ICU Medical, Inc.
(NASDAQ: ICUI). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Regeneron Pharmaceuticals, Inc. Research Report

On November 7, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) along with
Bayer HealthCare (Bayer) announced the submission of an application by Bayer
for the marketing authorization of EYLEA® (aflibercept) Injection for the
treatment of patients with Diabetic Macular Edema in the European Union.
Regeneron stated that it has also submitted a supplemental Biologic Licensing
Application (BLA) for EYLEA in this indication to the U.S. Food and Drug
Administration (FDA). George D. Yancopoulos, M.D., Ph. D., Chief Scientific
Officer of Regeneron and President of Regeneron Laboratories said, "Diabetes
is a growing, worldwide health concern and DME is a major cause of vision loss
in those with diabetic retinopathy. We are pleased with this regulatory
submission in a third indication for EYLEA in Europe and, if approved, hope to
be able to offer physicians and patients a new treatment option." According to
the release, Bayer HealthCare and Regeneron are collaborating on the global
development of EYLEA, wherein Regeneron maintains exclusive rights to EYLEA in
the United States and Bayer licensed the exclusive marketing rights outside
the United States. The Full Research Report on Regeneron Pharmaceuticals, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8ea7_REGN

--

Dendreon Corp. Research Report

On November 12, 2013, Dendreon Corp. (Dendreon) reported its Q3 2013 financial
results with net product revenue of $68 million compared to $77.9 million in
Q3 2012. Net loss for the quarter totaled $67.2 million or $0.44 per diluted
share compared to a net loss of $154.9 million or $1.04 per diluted share in
Q3 2012. As of September 30, 2013, the Company had a total of $233.3 million
in cash, cash equivalents, and short-term and long-term investments. John H.
Johnson, Chairman, President and CEO of Dendreon said, "We have seen a
strengthening of our business during the past two months. In fact, in October,
we saw more patient enrollments than any other month this year. Should these
enrollments convert to infusions at our historical rate, we expect that this
will bring benefit to both the fourth quarter of this year and the first
quarter of next year." The Full Research Report on Dendreon Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/de0c_DNDN

--

Dyax Corp. Research Report

On October 18, 2013, Dyax Corp. (Dyax) announced that the underwriters of its
earlier announced public offering have exercised their option to purchase an
additional 1,384,615 shares of the Company's common stock at a price to the
public of $6.50 per share. Dyax stated that after including net proceeds from
the exercise of option, the aggregate net proceeds from the offering totals
approximately $64.7 million, after deducting the underwriting discount and
other estimated offering expenses. The Company added that it plans to use the
net proceeds from this offering to fund research and development activities,
including the development of DX-2930, a therapeutic candidate for the
prophylactic treatment of hereditary angioedema (HAE), and for general
corporate purposes. The Full Research Report on Dyax Corp. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/58ae_DYAX

--

Techne Corp. Research Report

On October 29, 2013, Techne Corp. (Techne) reported its Q1 FY 2014 financial
results (period ended September 30, 2013) with net sales of $85.7 million, up
14.2% YoY. Net earnings arrived at $27.4 million or $0.74 per diluted share
compared to $25.7million or $0.70 per diluted share in Q1 FY 2013. Adjusted
earnings totaled $30.7 million, up 11.6% YoY, while cash generated from
operations for the quarter increased by 11.4% YoY to $32.6 million. Capital
expenditures for the quarter were $3.8 million. The Full Research Report on
Techne Corp. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b071_TECH

--

ICU Medical, Inc. Research Report

On October 21, 2013, ICU Medical Inc. (ICU Medical) announced that Dr. George
Lopez will step down as the Company's President and CEO due to health reasons.
The Company stated that he will continue in his role as Chairman of the Board
and will remain an employee in the Research and Development Department. ICU
Medical also announced that its Board of Directors has appointed Steven Riggs,
current Vice President of Operations, as acting CEO, with immediate effect.
According to the Company, Mr. Riggs has served as Vice President of Operations
since 2002, wherein he was responsible for all of the Company's worldwide
operations, including management of its supply chain. Dr. Michael Kovalchik,
Lead Director of ICU Medical said, "The Board has complete confidence that
Steven Riggs is the right person during this period. Steven's many years of
service to ICU Medical have demonstrated remarkable talent in improving our
efficiencies, driving our Company as a low cost leader, and positioning us for
profitable expansion." The Full Research Report on ICU Medical, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/be3b_ICUI

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.

1.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
2.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
3.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.